Cadila Healthcare Receives Final USFDA Nod For Acyclovir


Cadila Healthcare on Thursday announced that Zydus Cadila has received final approval from the U.S FDA to market Acyclovir for injection USP in the strengths of 500 mg/vial and 1000 mg/vial.

Acyclovir for Injection USP, which caters to the anti-viral segment will be produced at the group’s formulations manufacturing facility at Moraiya, Ahemdabad.

The group now has more than 120 approvals and has filed over 300 ANDAs, since the commencement of the filing process in FY2003-2004.

Cadila Healthcare on the NSE was trading at Rs 538 per share higher by Rs 9 per share or 1.7% at 1016 hours. The stock has delivered 68% return in one year time period and has outperformed the BSE Sensex and BSE Healthcare indices over the same time period.

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: